OxFORD Asset Management LLP bought a new stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 14,580 shares of the medical equipment provider’s stock, valued at approximately $1,686,000.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Bessemer Group Inc. grew its holdings in Zimmer Biomet by 21.1% during the 2nd quarter. Bessemer Group Inc. now owns 4,297 shares of the medical equipment provider’s stock valued at $552,000 after buying an additional 750 shares in the last quarter. Trexquant Investment LP purchased a new position in Zimmer Biomet during the 2nd quarter valued at approximately $231,000. Canada Pension Plan Investment Board grew its holdings in Zimmer Biomet by 7.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 51,861 shares of the medical equipment provider’s stock valued at $6,659,000 after buying an additional 3,700 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Zimmer Biomet by 1.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 669,622 shares of the medical equipment provider’s stock valued at $85,980,000 after buying an additional 7,273 shares in the last quarter. Finally, First Trust Advisors LP grew its holdings in Zimmer Biomet by 21.4% during the 2nd quarter. First Trust Advisors LP now owns 107,055 shares of the medical equipment provider’s stock valued at $13,746,000 after buying an additional 18,863 shares in the last quarter. 86.24% of the stock is currently owned by institutional investors.
Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) traded up $2.42 during trading on Friday, hitting $115.24. The stock had a trading volume of 2,125,344 shares, compared to its average volume of 1,250,446. The stock has a market cap of $23,332.99, a PE ratio of 14.28, a price-to-earnings-growth ratio of 1.79 and a beta of 1.15. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings Inc has a 12-month low of $100.87 and a 12-month high of $133.49.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. Zimmer Biomet’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.79 EPS. equities analysts expect that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current year.
Several equities analysts have weighed in on the company. BMO Capital Markets restated a “buy” rating and set a $142.00 price target on shares of Zimmer Biomet in a report on Tuesday, December 12th. Stifel Nicolaus restated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. TheStreet cut Zimmer Biomet from a “b-” rating to a “c+” rating in a report on Friday, November 24th. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, Piper Jaffray Companies cut Zimmer Biomet from an “overweight” rating to a “neutral” rating in a report on Thursday, November 2nd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $134.05.
TRADEMARK VIOLATION WARNING: “OxFORD Asset Management LLP Takes $1.69 Million Position in Zimmer Biomet Holdings Inc (ZBH)” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/12/17/oxford-asset-management-llp-takes-1-69-million-position-in-zimmer-biomet-holdings-inc-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.